298 related articles for article (PubMed ID: 37338722)
1. COVID-19 pandemic and adrenals: deep insights and implications in patients with glucocorticoid disorders.
Cozzolino A; Hasenmajer V; Newell-Price J; Isidori AM
Endocrine; 2023 Oct; 82(1):1-14. PubMed ID: 37338722
[TBL] [Abstract][Full Text] [Related]
2. Management of Patients With Glucocorticoid-Related Diseases and COVID-19.
Chifu I; Detomas M; Dischinger U; Kimpel O; Megerle F; Hahner S; Fassnacht M; Altieri B
Front Endocrinol (Lausanne); 2021; 12():705214. PubMed ID: 34594302
[TBL] [Abstract][Full Text] [Related]
3. Adrenal Insufficiency and Glucocorticoid Use During the COVID-19 Pandemic.
Almeida MQ; Mendonca BB
Clinics (Sao Paulo); 2020; 75():e2022. PubMed ID: 32555949
[TBL] [Abstract][Full Text] [Related]
4. Adrenal Gland Function and Dysfunction During COVID-19.
Kanczkowski W; Gaba WH; Krone N; Varga Z; Beuschlein F; Hantel C; Andoniadou C; Bornstein SR
Horm Metab Res; 2022 Aug; 54(8):532-539. PubMed ID: 35944524
[TBL] [Abstract][Full Text] [Related]
5. COVID-19, adrenal gland, glucocorticoids, and adrenal insufficiency.
Akbas EM; Akbas N
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2021 Mar; 165(1):1-7. PubMed ID: 33542545
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid excess and COVID-19 disease.
Guarnotta V; Ferrigno R; Martino M; Barbot M; Isidori AM; Scaroni C; Ferrante A; Arnaldi G; Pivonello R; Giordano C
Rev Endocr Metab Disord; 2021 Dec; 22(4):703-714. PubMed ID: 33025384
[TBL] [Abstract][Full Text] [Related]
7. Practical Considerations for the Management of Cushing's Disease and COVID-19: A Case Report.
Beretta F; Dassie F; Parolin M; Boscari F; Barbot M; Busetto L; Mioni R; De Carlo E; Scaroni C; Fallo F; Vettor R; Maffei P
Front Endocrinol (Lausanne); 2020; 11():554. PubMed ID: 33071957
[No Abstract] [Full Text] [Related]
8. Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.
Yuen KCJ; Mortensen MJ; Azadi A; Fonkem E; Findling JW
Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00246. PubMed ID: 34268454
[TBL] [Abstract][Full Text] [Related]
9. Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic.
Yuen KCJ; Blevins LS; Findling JW
Endocr Pract; 2020 Aug; 26(8):915-922. PubMed ID: 33471683
[TBL] [Abstract][Full Text] [Related]
10. Frequently Asked Questions in Patients With Adrenal Insufficiency in the Time of COVID-19.
Sabbadin C; Betterle C; Scaroni C; Ceccato F
Front Endocrinol (Lausanne); 2021; 12():805647. PubMed ID: 35002978
[TBL] [Abstract][Full Text] [Related]
11. [Practical recommendations for screening and management of functional disorders of the adrenal cortex in cases of SARS-CoV-2 infections].
Masjkur J; Barthel A; Kanczkowski W; Müller G; Bornstein SR
Internist (Berl); 2022 Jan; 63(1):4-11. PubMed ID: 34928398
[TBL] [Abstract][Full Text] [Related]
12. Impact of COVID-19 pandemic on psychophysical stress in patients with adrenal insufficiency: the CORTI-COVID study.
Martino M; Aboud N; Cola MF; Giancola G; Ciarloni A; Salvio G; Arnaldi G
J Endocrinol Invest; 2021 May; 44(5):1075-1084. PubMed ID: 32946078
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 infection: from stress-related cortisol levels to adrenal glands infarction.
Popescu M; Terzea DC; Carsote M; Ghenea AE; Costache A; Popescu IAS; Biciuşcă V; Busuioc CJ; Ghemigian AM
Rom J Morphol Embryol; 2022; 63(1):39-48. PubMed ID: 36074666
[TBL] [Abstract][Full Text] [Related]
14. Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess.
Vogel F; Reincke M
Rev Endocr Metab Disord; 2022 Apr; 23(2):233-250. PubMed ID: 34241765
[TBL] [Abstract][Full Text] [Related]
15. The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO International Expert Panel.
Jensterle M; Herman R; Janež A; Mahmeed WA; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Galia M; Goh SY; Kalra S; Kempler P; Lessan N; Lotufo P; Papanas N; Rizvi AA; Santos RD; Stoian AP; Toth PP; Viswanathan V; Rizzo M
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806331
[TBL] [Abstract][Full Text] [Related]
16. What we have to know about corticosteroids use during Sars-Cov-2 infection.
Ferraù F; Ceccato F; Cannavò S; Scaroni C
J Endocrinol Invest; 2021 Apr; 44(4):693-701. PubMed ID: 32860209
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool.
Minnetti M; Hasenmajer V; Sbardella E; Angelini F; Simeoli C; Di Paola N; Cozzolino A; Pivonello C; De Alcubierre D; Chiloiro S; Baldelli R; De Marinis L; Pivonello R; Pofi R; Isidori AM
Eur J Endocrinol; 2022 Nov; 187(5):719-731. PubMed ID: 36102827
[TBL] [Abstract][Full Text] [Related]
18. ChAdOx1 SARS-CoV-2 vaccination: A putative precipitant of adrenal crises.
Maguire D; McLaren DS; Rasool I; Shah PM; Lynch J; Murray RD
Clin Endocrinol (Oxf); 2023 Nov; 99(5):470-473. PubMed ID: 34358373
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and metabolic impact of glucocorticoid replacement therapy.
Johannsson G; Ragnarsson O
Front Horm Res; 2014; 43():33-44. PubMed ID: 24943296
[TBL] [Abstract][Full Text] [Related]
20. New Insights on Effects of Glucocorticoids in Patients With SARS-CoV-2 Infection.
Shacham EC; Ishay A
Endocr Pract; 2022 Oct; 28(10):1100-1106. PubMed ID: 35870803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
